BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

Search

Sanofi SA

Fermé

SecteurSoins de santé

92.54 -0.88

Résumé

Variation du prix de l'action

24h

Actuel

Min

92.18

Max

94.26

Chiffres clés

By Trading Economics

Revenu

-2.3B

499M

Ventes

-6.5B

7.6B

P/E

Moyenne du Secteur

20.663

57.333

BPA

1.31

Rendement du dividende

4.32

Marge bénéficiaire

6.539

Employés

82,878

EBITDA

-3.7B

563M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+22.28% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

4.32%

2.63%

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-20B

111B

Ouverture précédente

93.42

Clôture précédente

92.54

Score Technique

By Trading Central

Confiance

Neutral Evidence

Sanofi SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 avr. 2025, 08:52 UTC

Résultats

Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug -- Update

24 avr. 2025, 05:44 UTC

Résultats

Sanofi Sales, Profit Beat Expectations

9 avr. 2025, 06:00 UTC

Acquisitions, Fusions, Rachats

Santander Exploring Options to Sell Polish Unit Stake, Bloomberg Says, Citing Sources

20 mars 2025, 06:43 UTC

Acquisitions, Fusions, Rachats

Sanofi to Acquire Autoimmune Disease Treatment From Dren Bio for Up to $1.9 Billion

24 avr. 2025, 12:54 UTC

Market Talk
Résultats

Sanofi's Pipeline Updates Seem Mixed -- Market Talk

24 avr. 2025, 10:06 UTC

Market Talk
Résultats

Sanofi Starts the Year Strong -- Market Talk

10 avr. 2025, 12:06 UTC

Market Talk
Acquisitions, Fusions, Rachats

PKO's Hypothetical Acquisition of Santander's Polish Unit Could Increase Its Role in Sector -- Market Talk

10 avr. 2025, 09:10 UTC

Actions en Tendance

Stocks to Watch Thursday: Trump Media, U.S. Steel, Tesla, Barclays -- WSJ

9 avr. 2025, 10:49 UTC

Market Talk
Acquisitions, Fusions, Rachats

Erste Bank Seen as Potential Buyer for Santander's Polish Unit -- Market Talk

9 avr. 2025, 08:19 UTC

Market Talk
Acquisitions, Fusions, Rachats

Capital Deployment From Santander's Potential Poland Disposal Is Key Question -- Market Talk

9 avr. 2025, 06:59 UTC

Market Talk
Acquisitions, Fusions, Rachats

Potential Santander Polish Exit Less Compelling Than Sale of U.K. Bank -- Market Talk

9 avr. 2025, 06:46 UTC

Market Talk
Acquisitions, Fusions, Rachats

Santander's Potential Polish Operations Disposal Could Free Up Capital to Boost Returns Elsewhere -- Market Talk

4 avr. 2025, 09:07 UTC

Actions en Tendance

Stocks to Watch Friday: Glencore, Apple, Barclays -- WSJ

3 avr. 2025, 07:51 UTC

Market Talk

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

2 avr. 2025, 13:44 UTC

Market Talk

Santander Push Into Canada on the Cards -- Market Talk

2 avr. 2025, 09:27 UTC

Actions en Tendance

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

26 mars 2025, 06:19 UTC

Market Talk
Résultats

Santander Surpasses 100 Billion-Euro Valuation Milestone -- Market Talk

25 mars 2025, 10:08 UTC

Market Talk

Santander Needs Step-Up in Profitability to Fully Close Discount -- Market Talk

20 mars 2025, 09:00 UTC

Actualités

'Anti-Woke' in the U.S., DEI at Home: the New Playbook for European Companies -- WSJ

20 mars 2025, 06:05 UTC

Acquisitions, Fusions, Rachats

Sanofi: Deal Seeks to Broaden Immunology Pipeline

20 mars 2025, 06:05 UTC

Acquisitions, Fusions, Rachats

Sanofi to Make Potential Future Payments Totaling $1.3B Upon Reaching Milestones

20 mars 2025, 06:04 UTC

Acquisitions, Fusions, Rachats

Sanofi to Pay $600M Upfront

20 mars 2025, 06:02 UTC

Acquisitions, Fusions, Rachats

Sanofi to Buy Dren Bio's Bispecific Myeloid Cell Engager

20 mars 2025, 06:00 UTC

Acquisitions, Fusions, Rachats

Press Release: Sanofi To Acquire Dren Bio's Bispecific Myeloid Cell Engager For Deep B-cell Depletion, Broadening Immunology Pipeline >SAN.FR

18 mars 2025, 09:33 UTC

Actions en Tendance

Stocks to Watch Tuesday: Nvidia, BYD, Santander, Google -- WSJ

17 mars 2025, 23:00 UTC

Actualités

Santander Pushes to Expand U.S. Operations by Utilizing Verizon Customer Base -- WSJ

13 mars 2025, 09:50 UTC

Résultats

Santander Approves Final Cash Dividend Per Share of EUR11 cents

13 mars 2025, 09:49 UTC

Résultats

Santander Increased 2024 Cash Payments by 19%

24 févr. 2025, 08:56 UTC

Market Talk
Résultats

European Banks' Quarterly Beats Confirm Momentum -- Market Talk

24 févr. 2025, 08:30 UTC

Market Talk
Acquisitions, Fusions, Rachats

Southern European Banks' Strong Finish to 2024 Confirms Attractiveness -- Market Talk

Comparaison

Variation de prix

Sanofi SA prévision

Objectif de Prix

By TipRanks

22.28% hausse

Prévisions sur 12 Mois

Moyen 114.144 EUR  22.28%

Haut 127 EUR

Bas 83.729 EUR

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

14 ratings

10

Achat

4

Maintien

0

Vente

Score Technique

By Trading Central

91.62 / 93.4Support & Résistance

Court Terme

Neutral Evidence

Moyen Terme

Strong Bearish Evidence

Long Terme

Strong Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.